BACKGROUND:High plasma HIV-1 RNA concentrations are associated with increased risk of HIV-1 transmission. Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners. METHODS: Participants in our prospective cohort analysis were from a randomised placebo-controlled trial that enrolled heterosexual African adults who were seropositive for both HIV-1 and herpes simplex virus type 2, and their HIV-1 seronegative partners. At enrolment, HIV-1 infected participants had CD4 counts of 250 cells per microL or greater and did not meet national guidelines for ART initiation; during 24 months of follow-up, CD4 counts were measured every 6 months and ART was initiated in accordance with national guidelines. Uninfected partners were tested for HIV-1 every 3 months. The primary outcome was genetically-linked HIV-1 transmission within the study partnership. We assessed rates of HIV-1 transmission by ART status of infected participants. FINDINGS:3381 couples were eligible for analysis. 349 (10%) participants with HIV-1 initiated ART during the study, at a median CD4 cell count of 198 (IQR 161-265) cells per microL. Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0.37 (95% CI 0.09-2.04) per 100 person-years in those who had initiated treatment and 2.24 (1.84-2.72) per 100 person-years in those who had not-a 92% reduction (adjusted incidence rate ratio 0.08, 95% CI 0.00-0.57, p=0.004). In participants not on ART, the highest HIV-1 transmission rate (8.79 per 100 person-years) was from those with CD4 cell counts lower than 200 cells per microL. In couples in whom the untreated HIV-1 infected partner had a CD4 cell count greater than 200 cells per microL, 66 (70%) of 94 transmissions occurred when plasma HIV-1 concentrations exceeded 50 000 copies per mL. INTERPRETATION: Low CD4 cell counts and high plasma HIV-1 concentrations might guide use of ART to achieve an HIV-1 prevention benefit. Provision of ART to HIV-1 infected patients could be an effective strategy to achieve population-level reductions in HIV-1 transmission. FUNDING: Bill & Melinda Gates Foundation; US National Institutes of Health. Copyright 2010 Elsevier Ltd. All rights reserved.
RCT Entities:
BACKGROUND: High plasma HIV-1 RNA concentrations are associated with increased risk of HIV-1 transmission. Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners. METHODS:Participants in our prospective cohort analysis were from a randomised placebo-controlled trial that enrolled heterosexual African adults who were seropositive for both HIV-1 and herpes simplex virus type 2, and their HIV-1 seronegative partners. At enrolment, HIV-1 infectedparticipants had CD4 counts of 250 cells per microL or greater and did not meet national guidelines for ART initiation; during 24 months of follow-up, CD4 counts were measured every 6 months and ART was initiated in accordance with national guidelines. Uninfected partners were tested for HIV-1 every 3 months. The primary outcome was genetically-linked HIV-1 transmission within the study partnership. We assessed rates of HIV-1 transmission by ART status of infected participants. FINDINGS: 3381 couples were eligible for analysis. 349 (10%) participants with HIV-1 initiated ART during the study, at a median CD4 cell count of 198 (IQR 161-265) cells per microL. Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0.37 (95% CI 0.09-2.04) per 100 person-years in those who had initiated treatment and 2.24 (1.84-2.72) per 100 person-years in those who had not-a 92% reduction (adjusted incidence rate ratio 0.08, 95% CI 0.00-0.57, p=0.004). In participants not on ART, the highest HIV-1 transmission rate (8.79 per 100 person-years) was from those with CD4 cell counts lower than 200 cells per microL. In couples in whom the untreated HIV-1 infected partner had a CD4 cell count greater than 200 cells per microL, 66 (70%) of 94 transmissions occurred when plasma HIV-1 concentrations exceeded 50 000 copies per mL. INTERPRETATION: Low CD4 cell counts and high plasma HIV-1 concentrations might guide use of ART to achieve an HIV-1 prevention benefit. Provision of ART to HIV-1 infectedpatients could be an effective strategy to achieve population-level reductions in HIV-1 transmission. FUNDING: Bill & Melinda Gates Foundation; US National Institutes of Health. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Susan M Graham; Sarah E Holte; Norbert M Peshu; Barbra A Richardson; Dana D Panteleeff; Walter G Jaoko; Jeckoniah O Ndinya-Achola; Kishorchandra N Mandaliya; Julie M Overbaugh; R Scott McClelland Journal: AIDS Date: 2007-02-19 Impact factor: 4.177
Authors: Rebecca Bunnell; John Paul Ekwaru; Peter Solberg; Nafuna Wamai; Winnie Bikaako-Kajura; Willy Were; Alex Coutinho; Cheryl Liechty; Elizabeth Madraa; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Stanley Luchters; Avina Sarna; Scott Geibel; Matthew F Chersich; Paul Munyao; Susan Kaai; Kishorchandra N Mandaliya; Khadija S Shikely; Naomi Rutenberg; Marleen Temmerman Journal: AIDS Patient Care STDS Date: 2008-07 Impact factor: 5.078
Authors: A N Phillips; S Staszewski; R Weber; O Kirk; P Francioli; V Miller; P Vernazza; J D Lundgren; B Ledergerber Journal: JAMA Date: 2001-11-28 Impact factor: 56.272
Authors: Moses Bateganya; Grant Colfax; Leigh Anne Shafer; Cissy Kityo; Peter Mugyenyi; David Serwadda; Harriet Mayanja; David Bangsberg Journal: AIDS Patient Care STDS Date: 2005-11 Impact factor: 5.078
Authors: A Kaida; G Gray; F I Bastos; I Andia; M Maier; J McIntyre; B Grinsztejn; S A Strathdee; D R Bangsberg; R Hogg Journal: AIDS Care Date: 2008-01
Authors: Susan M Graham; Linnet Masese; Ruth Gitau; Zahra Jalalian-Lechak; Barbra A Richardson; Norbert Peshu; Kishor Mandaliya; James N Kiarie; Walter Jaoko; Jeckoniah Ndinya-Achola; Julie Overbaugh; R Scott McClelland Journal: J Infect Dis Date: 2010-10-05 Impact factor: 5.226
Authors: Jennifer N Sayles; Jacqueline Rurangirwa; Min Kim; Janni Kinsler; Rangell Oruga; Mike Janson Journal: AIDS Patient Care STDS Date: 2012-07-09 Impact factor: 5.078
Authors: Gail V Berkenblit; James M Sosman; Michael Bass; Hirut T Gebrekristos; Joseph Cofrancesco; Lynn E Sullivan; Robert L Cook; Marcia Edison; Philip G Bashook; P Todd Korthuis Journal: J Gen Intern Med Date: 2012-07 Impact factor: 5.128